AP804A - APO-B-secretion/MTP inhibitory amides. - Google Patents

APO-B-secretion/MTP inhibitory amides. Download PDF

Info

Publication number
AP804A
AP804A APAP/P/1997/001145A AP9701145A AP804A AP 804 A AP804 A AP 804A AP 9701145 A AP9701145 A AP 9701145A AP 804 A AP804 A AP 804A
Authority
AP
ARIPO
Prior art keywords
inhibitors
compounds
crc10
alkyl
crc4
Prior art date
Application number
APAP/P/1997/001145A
Other languages
English (en)
Other versions
AP9701145A0 (en
Inventor
George Chang
George J Quallich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701145A0 publication Critical patent/AP9701145A0/xx
Application granted granted Critical
Publication of AP804A publication Critical patent/AP804A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1997/001145A 1996-11-27 1997-11-20 APO-B-secretion/MTP inhibitory amides. AP804A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27
PCT/IB1997/001368 WO1998023593A1 (fr) 1996-11-27 1997-11-03 AMIDES INHIBANT LA SECRETION D'Apo B ET/OU LA PROTEINE MTP

Publications (2)

Publication Number Publication Date
AP9701145A0 AP9701145A0 (en) 1998-01-31
AP804A true AP804A (en) 2000-01-28

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001145A AP804A (en) 1996-11-27 1997-11-20 APO-B-secretion/MTP inhibitory amides.

Country Status (34)

Country Link
US (1) US6121283A (fr)
EP (1) EP0944602A1 (fr)
JP (1) JP3270764B2 (fr)
KR (1) KR100334567B1 (fr)
CN (2) CN1238764A (fr)
AP (1) AP804A (fr)
AR (1) AR010309A1 (fr)
AU (1) AU716151B2 (fr)
BG (2) BG108830A (fr)
BR (1) BR9714364A (fr)
CA (1) CA2272719C (fr)
CZ (1) CZ292160B6 (fr)
DZ (1) DZ2358A1 (fr)
EA (1) EA001539B1 (fr)
GT (1) GT199700122A (fr)
HN (1) HN1997000144A (fr)
HR (1) HRP970642A2 (fr)
ID (1) ID18995A (fr)
IL (1) IL129744A0 (fr)
IS (1) IS5040A (fr)
MA (1) MA26451A1 (fr)
NO (1) NO312760B1 (fr)
NZ (1) NZ335162A (fr)
OA (1) OA11050A (fr)
PA (1) PA8441601A1 (fr)
PE (1) PE17199A1 (fr)
SK (1) SK65499A3 (fr)
TN (1) TNSN97193A1 (fr)
TR (1) TR199901180T2 (fr)
TW (1) TW502023B (fr)
UY (1) UY24789A1 (fr)
WO (1) WO1998023593A1 (fr)
YU (1) YU23499A (fr)
ZA (1) ZA9710641B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
ATE233734T1 (de) * 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
CA2319495A1 (fr) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
WO2000021951A1 (fr) 1998-10-08 2000-04-20 Smithkline Beecham Plc Derives de tetrahydrobenzozepine utiles comme modulateurs des recepteurs de la la dopamine d3
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
WO2000038725A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinaisons utilisees dans le cadre de troubles cardio-vasculaires
HUP0201972A3 (en) * 1998-12-23 2005-06-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
WO2001005767A1 (fr) * 1999-07-20 2001-01-25 Novartis Ag Composes organiques
CO5271688A1 (es) * 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
CA2324800A1 (fr) * 1999-11-10 2001-05-10 Mary Anne Hickman Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp
CA2324801A1 (fr) * 1999-11-10 2001-05-10 Andrew Gordon Swick Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
PT1259484E (pt) * 2000-01-18 2005-09-30 Novartis Ag Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b
CA2402431C (fr) * 2000-03-14 2009-10-06 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tetrahydroisoquinoline
AU2001262185A1 (en) * 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
WO2002014277A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
CZ2003593A3 (cs) * 2000-09-01 2003-05-14 Sankyo Company Limited Farmaceutický přípravek pro léčbu a prevenci xantomu a aterosklerózy
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
CZ20031230A3 (cs) * 2000-10-05 2003-10-15 Fujisawa Pharmaceutial Co., Ltd Benzamidový derivát a farmaceutický prostředek
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US20040157866A1 (en) * 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
OA12626A (en) 2001-06-28 2006-06-13 Pfizer Prod Inc triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP)and/or apolipoprotein B(APO B) secretion.
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
WO2003013516A1 (fr) * 2001-08-10 2003-02-20 Adipogenix, Inc. Composes servant a moduler l'accumulation des graisses
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
WO2003072532A1 (fr) 2002-02-28 2003-09-04 Japan Tobacco Inc. Compose d'esters et ses utilisation en medecine
US7241774B2 (en) * 2002-03-13 2007-07-10 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (fr) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
BR0317323A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicerìdeos microssomal
AU2003286347A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
WO2005021486A1 (fr) 2003-08-29 2005-03-10 Japan Tobacco Inc. Derive d'ester et utilisation medicale de celui-ci
PL1751111T3 (pl) 2004-03-01 2015-06-30 Actelion Pharmaceuticals Ltd Podstawione pochodne 1,2,3,4-tetrahydroizochinoliny
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (fr) * 2004-10-25 2006-05-04 Japan Tobacco Inc. Préparation médicinale solide améliorée en termes de solubilité et de stabilité et procédé servant à produire celle-ci
EP1843819A2 (fr) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Procedes de reduction de la graisse corporelle
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
EP1877369B1 (fr) 2005-04-19 2013-07-10 Surface Logix, Inc. Inhibiteurs des secretions microsomales des apo-b et des proteines de transfert des triglycerides
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2009531314A (ja) * 2006-03-10 2009-09-03 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
JP5198430B2 (ja) 2006-04-03 2013-05-15 サンタリス ファーマ アー／エス ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
MY162210A (en) * 2006-04-03 2017-05-31 Roche Innovation Ct Copenhagen As Pharmaceutical composition
CA2654183A1 (fr) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions et procedes pour ameliorer l'hyperlipidemie
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
EP2076597A2 (fr) * 2006-10-09 2009-07-08 Santaris Pharma A/S Composés antagonistes de l'arn pour la modulation de pcsk9
WO2008045564A2 (fr) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
KR101387459B1 (ko) * 2006-10-24 2014-05-14 얀센 파마슈티카 엔.브이. Ｍｔｐ를 저해하는 테트라하이드로-나프탈렌-1-카복실산 유도체
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008075949A1 (fr) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation de l'expression génique d'une protéine microsomale de transfert des triglycérides (mtp ou mttp) au moyen de microorganismes alimentaires ingérés/de qualité alimentaire
EP2120927A1 (fr) * 2006-12-21 2009-11-25 Aegerion Pharmaceuticals, Inc. Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol
WO2008113832A2 (fr) * 2007-03-22 2008-09-25 Santaris Pharma A/S Composés arn antagonistes courts pour la modulation de l'arnm cible
JP2010521193A (ja) * 2007-03-22 2010-06-24 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物
EP2162451A4 (fr) * 2007-06-25 2012-04-18 Neurogen Corp Composés de pipérazinyl oxoalkyl tétrahydro-bêta-carbolines et analogues apparentés
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
DK2225261T3 (en) 2007-12-03 2016-06-06 Obe Therapy Biotechnology Borpeptidinhibitorer of enteropeptidase and their uses in the treatment of obesity, obesity and / or disorders associated with abnormal lipid metabolism
CN101925383A (zh) 2007-12-11 2010-12-22 赛特帕斯凡德株式会社 甲酰胺化合物及其作为趋化因子受体激动剂的应用
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
AU2009221064B2 (en) * 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
EP2315832B1 (fr) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (fr) 2009-07-21 2011-01-27 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
KR101695582B1 (ko) 2013-04-17 2017-01-13 화이자 인코포레이티드 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
RS59986B1 (sr) 2013-06-27 2020-03-31 Roche Innovation Ct Copenhagen As Antisens oligomeri i konjugati koji ciljno deluju na pcsk9
WO2015065595A1 (fr) 2013-10-30 2015-05-07 Trustees Of Dartmouth College Procédé d'inhibition sélective d'acat1 dans le traitement de l'obésité, du syndrome métabolique et de l'athérosclérose
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
CA2965336A1 (fr) * 2014-10-22 2016-04-28 The Board Of Regents Of The University Of Texas System Inhibiteurs a petites molecules ciblant le recepteur du domaine discoidine 1 et ses utilisations
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (fr) * 1993-09-03 1995-03-15 Bristol-Myers Squibb Company Inhibiteurs de la protéine microsomale de transfert des triglycerides
WO1996026205A1 (fr) * 1995-02-21 1996-08-29 Bristol-Myers Squibb Company Inhibiteurs de la proteine microsomiale de transfert des triglycerides et procede d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040640A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (fr) * 1993-09-03 1995-03-15 Bristol-Myers Squibb Company Inhibiteurs de la protéine microsomale de transfert des triglycerides
WO1996026205A1 (fr) * 1995-02-21 1996-08-29 Bristol-Myers Squibb Company Inhibiteurs de la proteine microsomiale de transfert des triglycerides et procede d'utilisation

Also Published As

Publication number Publication date
US6121283A (en) 2000-09-19
AR010309A1 (es) 2000-06-07
IL129744A0 (en) 2000-02-29
TR199901180T2 (xx) 1999-08-23
TW502023B (en) 2002-09-11
BG108830A (bg) 2005-10-31
WO1998023593A1 (fr) 1998-06-04
ID18995A (id) 1998-05-28
SK65499A3 (en) 2001-05-10
OA11050A (en) 2002-03-07
PA8441601A1 (es) 2000-05-24
CN1380289A (zh) 2002-11-20
AP9701145A0 (en) 1998-01-31
AU716151B2 (en) 2000-02-17
BG103434A (en) 2000-07-31
AU4634797A (en) 1998-06-22
UY24789A1 (es) 2000-09-29
HRP970642A2 (en) 1998-10-31
NO992525L (no) 1999-05-26
PE17199A1 (es) 1999-02-19
GT199700122A (es) 1999-05-19
DZ2358A1 (fr) 2002-12-28
JP3270764B2 (ja) 2002-04-02
CZ292160B6 (cs) 2003-08-13
EA001539B1 (ru) 2001-04-23
NO312760B1 (no) 2002-07-01
YU23499A (sh) 2001-07-10
BR9714364A (pt) 2000-03-21
CA2272719C (fr) 2002-10-01
CA2272719A1 (fr) 1998-06-04
TNSN97193A1 (fr) 2005-03-15
EA199900416A1 (ru) 1999-12-29
HN1997000144A (es) 1997-12-16
JP2000505810A (ja) 2000-05-16
NO992525D0 (no) 1999-05-26
CN1238764A (zh) 1999-12-15
NZ335162A (en) 2000-01-28
MA26451A1 (fr) 2004-12-20
ZA9710641B (en) 1999-05-26
IS5040A (is) 1999-04-30
EP0944602A1 (fr) 1999-09-29
KR100334567B1 (ko) 2002-05-03
KR20000057269A (ko) 2000-09-15

Similar Documents

Publication Publication Date Title
AP804A (en) APO-B-secretion/MTP inhibitory amides.
KR101186386B1 (ko) Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
US6121304A (en) Pentafluorobenzenesulfonamides and analogs
JP5989923B2 (ja) メチル基変更酵素の調節物質、組成物及びその使用
US7291644B2 (en) Indole derivatives
EP2593428B1 (fr) N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
US9096532B2 (en) Pyrazole inhibitors of COX-2 and sEH
McKew et al. Indole Cytosolic Phospholipase A2 α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3, 4-dichlorobenzyl) sulfonyl] amino} ethyl)-1-(diphenylmethyl)-1 H-indol-3-yl] propyl} benzoic Acid, Efipladib
JP6866514B2 (ja) Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
AU2015219920B2 (en) Triazine compound and use thereof for medical purposes
PT2004607E (pt) Derivados de ácido (4-(4-[6-(trifluorometil-piridin-3- -ilamino)-heteroaril contendo n]-fenil)-ciclo-hexil)- -acético e seus usos farmacêuticos
JP2007501263A (ja) ペルオキシソーム増殖因子活性化受容体のリガンドとしてのｎ−アシル窒素ヘテロ環
EP2424517A1 (fr) Dérivés d'acide sulfamoyl benzoïque en tant qu'antagonistes de trpm8
EA016345B1 (ru) Новые сульфонилпирролы в качестве ингибиторов гдац (гистондезацетилазы)
JP2016516804A (ja) 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN101146530A (zh) 用于治疗高血压的3,4-取代的吡咯烷衍生物
CN1980894A (zh) 作为ppar调节剂的化合物和组合物
KR20200015888A (ko) Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체
CN101223140A (zh) 可用于诊断性和治疗性处置依赖于肾素活性的疾病的哌啶衍生物
US7135495B2 (en) Indole derivatives
Yuan et al. Discovery of 2-azetidinone and 1H-pyrrole-2, 5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors
US20160102074A1 (en) Substituted amide compounds
He et al. Design, synthesis and molecular docking of amide and urea derivatives as Escherichia coli PDHc-E1 inhibitors
US11261154B2 (en) Benzene derivative
Takahashi et al. Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid